SCHEMBL4715409

SCHEMBL4715409

CCOC(=O)C(CC(C)C)C(=O)CBr

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
TRPA1 O75762 1/20 0.43
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MME P08473 1/20 0.33
GAA P10253 2/20 0.32
ALOX15 P16050 1/20 0.32
MGAM O43451 1/20 0.32
SI P14410 1/20 0.32
MGAM2 Q2M2H8 1/20 0.32
SOAT1 P35610 1/20 0.32
PPID Q08752 1/20 0.32
MMP8 P22894 2/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C19 P33261 1/20 0.32
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27617570 0.84 SOAT1 (0.39) ALDH1A1LMNAHSD17B10TDP1MEN1
SCHEMBL335607 0.83 ALDH1A1 (0.43) ALDH1A1TRPA1LMNAHSD17B10TDP1
SCHEMBL15437255 0.82 ALDH1A1 (0.48) ALDH1A1TRPA1LMNAHSD17B10TDP1
SCHEMBL10807025 0.81 ALDH1A1 (0.42) ALDH1A1TRPA1LMNAHSD17B10TDP1
SCHEMBL489304 0.79 MME (0.43) ALDH1A1LMNAHSD17B10TDP1MME
SCHEMBL5141925 0.79 GAA (0.50) ALDH1A1TRPA1LMNAKMT2AMME
SCHEMBL7624689 0.78 MME (0.42) ALDH1A1LMNAHSD17B10TDP1MME
SCHEMBL179900 0.78 ALDH1A1 (0.42) ALDH1A1LMNAHSD17B10TDP1MEN1
SCHEMBL6895465 0.76 ALOX15 (0.44) ALDH1A1LMNAHSD17B10TDP1MEN1
SCHEMBL9364109 0.76 TSHR (0.41) ALDH1A1LMNAHSD17B10TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1248612-B1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA LTD (CA) 2008-02-27 EP disclosed
EP-1248612-A4 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA INC (CA) 2005-09-07 EP disclosed
US-6525036-B2 Treating post-menopausal osteoporosis. MERCK & CO., INC. 2003-02-25 US disclosed
EP-1248612-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA INC. (CA) 2002-10-16 EP disclosed
US-20020052378-A1 Novel compounds and compositions as protease inhibitors Celera Corporation 2002-05-02 US disclosed
WO-2001049288-A9 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA INC (CA) 2001-10-25 WO disclosed
WO-2001049288-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052378-A1 Novel compounds and compositions as protease inhibitors SERPINB1, CTRL, SPINT2 ALDH1A1 1987/4885TRPA1 2783/4885LMNA 2284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.